High Prevalence of Constitutional Mismatch Repair Deficiency in a Pediatric T-cell Lymphoblastic Lymphoma Cohort.


Journal

HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 08 09 2021
accepted: 26 10 2021
entrez: 29 12 2021
pubmed: 30 12 2021
medline: 30 12 2021
Statut: epublish

Résumé

This study describes the clinical characteristics of a complete Dutch T-cell lymphoblastic lymphoma (T-LBL) cohort, including second primary malignancies and comorbidities. We show that over 10% of patients in this complete T-LBL cohort have been diagnosed with a cancer predisposition syndrome (CPS), consisting almost exclusively of constitutional mismatch repair deficiency (CMMRD). The clinical characteristics of sporadic T-LBL patients were compared with T-LBL patients that have been diagnosed with CMMRD. This shows that disease presentation is comparable but that disease localization in CMMRD patients might be more localized. The percentage of CPS seems reliable considering the completeness of the cohort of Dutch T-LBL patients and might even be an underestimation (possibility of undiagnosed CPS patients in cohort). As the frequency of an underlying predisposition syndrome among T-LBL patients may be underestimated at present, we advocate for screening all pediatric T-LBL patients for the presence of germline mutations in mismatch repair genes.

Identifiants

pubmed: 34964038
doi: 10.1097/HS9.0000000000000668
pmc: PMC8697338
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e668

Informations de copyright

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

Références

Semin Oncol. 1980 Sep;7(3):332-9
pubmed: 7414342
J Med Genet. 2014 Jun;51(6):355-65
pubmed: 24737826
Anemia. 2012;2012:865170
pubmed: 22701786
Blood. 2021 Apr 29;137(17):2347-2359
pubmed: 33152759
Haematologica. 2017 Dec;102(12):2086-2096
pubmed: 28983060
Haematologica. 2018 May;103(5):830-839
pubmed: 29449434
Clin Genet. 2013 Mar;83(3):238-43
pubmed: 22577899
J Clin Oncol. 2015 Jun 20;33(18):2112-8
pubmed: 25940716
Blood Adv. 2020 Jul 28;4(14):3466-3473
pubmed: 32722786
Nat Med. 2011 Sep 25;17(10):1298-303
pubmed: 21946537
Leukemia. 2021 Feb;35(2):534-549
pubmed: 32393843
Eur J Med Genet. 2016 Mar;59(3):116-25
pubmed: 26825391

Auteurs

Emma Kroeze (E)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Dilys D Weijers (DD)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Melanie M Hagleitner (MM)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Hester A de Groot-Kruseman (HA)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Marjolijn C J Jongmans (MCJ)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Department of Genetics, University Medical Center Utrecht, The Netherlands.

Roland P Kuiper (RP)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Department of Genetics, University Medical Center Utrecht, The Netherlands.

Rob Pieters (R)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Jules P P Meijerink (JPP)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Jan L C Loeffen (JLC)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Classifications MeSH